Atrial secondary tricuspid regurgitation: pathophysiology, definition, diagnosis, and treatment.

Atrial fibrillation Atrial functional tricuspid regurgitation Secondary tricuspid regurgitation Transcatheter interventions Tricuspid regurgitation Tricuspid valve

Journal

European heart journal
ISSN: 1522-9645
Titre abrégé: Eur Heart J
Pays: England
ID NLM: 8006263

Informations de publication

Date de publication:
14 Mar 2024
Historique:
received: 11 09 2023
revised: 03 01 2024
accepted: 30 01 2024
medline: 18 3 2024
pubmed: 5 3 2024
entrez: 5 3 2024
Statut: ppublish

Résumé

Atrial secondary tricuspid regurgitation (A-STR) is a distinct phenotype of secondary tricuspid regurgitation with predominant dilation of the right atrium and normal right and left ventricular function. Atrial secondary tricuspid regurgitation occurs most commonly in elderly women with atrial fibrillation and in heart failure with preserved ejection fraction in sinus rhythm. In A-STR, the main mechanism of leaflet malcoaptation is related to the presence of a significant dilation of the tricuspid annulus secondary to right atrial enlargement. In addition, there is an insufficient adaptive growth of tricuspid valve leaflets that become unable to cover the enlarged annular area. As opposed to the ventricular phenotype, in A-STR, the tricuspid valve leaflet tethering is typically trivial. The A-STR phenotype accounts for 10%-15% of clinically relevant tricuspid regurgitation and has better outcomes compared with the more prevalent ventricular phenotype. Recent data suggest that patients with A-STR may benefit from more aggressive rhythm control and timely valve interventions. However, little is mentioned in current guidelines on how to identify, evaluate, and manage these patients due to the lack of consistent evidence and variable definitions of this entity in recent investigations. This interdisciplinary expert opinion document focusing on A-STR is intended to help physicians understand this complex and rapidly evolving topic by reviewing its distinct pathophysiology, diagnosis, and multi-modality imaging characteristics. It first defines A-STR by proposing specific quantitative criteria for defining the atrial phenotype and for discriminating it from the ventricular phenotype, in order to facilitate standardization and consistency in research.

Identifiants

pubmed: 38441886
pii: 7619331
doi: 10.1093/eurheartj/ehae088
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

895-911

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.

Auteurs

Denisa Muraru (D)

Department of Medicine and Surgery, University of Milano-Bicocca, Piazza dell'Ateneo Nuovo 1, Milan 20126, Italy.
Department of Cardiology, Istituto Auxologico Italiano, IRCCS, Piazzale Brescia 20, Milan 20149, Italy.

Luigi P Badano (LP)

Department of Medicine and Surgery, University of Milano-Bicocca, Piazza dell'Ateneo Nuovo 1, Milan 20126, Italy.
Department of Cardiology, Istituto Auxologico Italiano, IRCCS, Piazzale Brescia 20, Milan 20149, Italy.

Rebecca T Hahn (RT)

Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.

Roberto M Lang (RM)

Department of Medicine, Section of Cardiology, University of Chicago Medical Center, Chicago, IL, USA.

Victoria Delgado (V)

Department of Cardiology, Hospital University Germans Trias I Pujol, Badalona, Spain.

Nina C Wunderlich (NC)

Department of Cardiology, Asklepios Klinik Langen, Langen, Germany.

Erwan Donal (E)

CHU Rennes, Inserm, University of Rennes 1, Rennes, France.

Maurizio Taramasso (M)

Department of Cardiac Surgery, HerzZentrum Hirslanden Zürich, Zürich, Switzerland.

Alison Duncan (A)

Heart Division, The Royal Brompton Hospital, London, UK.

Philipp Lurz (P)

Department of Cardiology, Heart Center Leipzig, Leipzig, Germany.
Department of Cardiology and Heart Valve Center, Universitätsmedizin Johannes Gutenberg-University, Langenbeckstr, Mainz 55131, Germany.

Tom De Potter (T)

Cardiovascular Center, OLV Hospital, Aalst, Belgium.

José L Zamorano Gómez (JL)

Department of Cardiology, University Hospital Ramón y Cajal, Ctra Colmenar Viejo Km 9.1, Madrid, Spain.

Jeroen J Bax (JJ)

Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.

Ralph Stephan von Bardeleben (RS)

Department of Cardiology and Heart Valve Center, Universitätsmedizin Johannes Gutenberg-University, Langenbeckstr, Mainz 55131, Germany.

Maurice Enriquez-Sarano (M)

Valve Science Center, Minneapolis Heart Institute Foundation, Minneapolis, MN, USA.

Francesco Maisano (F)

Valve Center IRCCS Ospedale San Raffaele, Cardiac Surgery, University Vita Salute, Milan, Italy.

Fabien Praz (F)

Department of Cardiology, Bern University Hospital, University of Bern, Freiburgstrasse 18, 3010 Bern, Switzerland.

Marta Sitges (M)

Cardiovascular Institute, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
CIBER, Centro de Investigación Biomédica en Red, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH